


AMENDMENTS TO THE CLAIMS

Claim 1. (Currently amended) A compound which conforms to the general formula I:




Wherein

W represents a 5 to 7 atoms cycloalkyl or heterocycloalkyl ring;

R₁ and R₂ represent independently hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C₁-C₆-alkoxy or R₁ and R₂ together can form a C₃-C₇-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula




R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or

heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently -C(R₃)=, -C(R₃)=C(R₄)-, -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR₈C(=O)-, NR₈S(=O)₂-, -C(=O)NR₈-, -S-, -S(=O)-, -S(=O)₂-, -S(=O)₂NR₈-, -C(=O)-O-, -O-C(=O)-, -C(=NR₈)NR₉-, C(=NOR₈)NR₉-, -NR₈C(=NOR₉)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula



R₃, R₄, R₅ and R₆ independently are as defined above;

D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;

B represents a single bond, -C(=O)-C₀-C₂-alkyl-, -C(=O)-C₂-C₆-alkenyl-, -C(=O)-C₂-C₆-alkynyl-, -C(=O)-O-, -C(=O)NR₈-C₀-C₂-alkyl-, -C(=NR₈)NR₉-S(=O)-C₀-C₂-

alkyl-, $-\text{S}(=\text{O})_2\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{S}(=\text{O})_2\text{NR}_8\text{C}_0\text{C}_2\text{-alkyl-}$, $\text{C}(\text{=NR}_8)\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{C}(\text{=NOR}_8)\text{C}_0\text{C}_2\text{-alkyl-}$ or $-\text{C}(\text{=NOR}_8)\text{NR}_9\text{C}_0\text{C}_2\text{-alkyl-}$;
 R_8 and R_9 , independently are as defined above;


any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds

but excluding the following compounds

4-(3-phenyl-oxadiazol-5-yl)-N-(4-bromophenyl)aminocarbonylpiperidine
N-benzoyl-3-(3,4-dimethoxyphenylaminocarbonyl)-piperidin-4-one
N-(3-cyanophenylmethylcarbonyl)-4-(3-(2,3-dichlorophenyl)-pyrazo-5-yl)piperidine.


Claim 2. (Currently amended) A compound according to claim 1 having the formula I-A



Wherein

R_1 and R_2 represent independently hydrogen, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_2\text{-C}_6\text{-alkenyl}$, $\text{C}_2\text{-C}_6\text{-alkynyl}$, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, $\text{C}_1\text{-C}_6\text{-alkoxy}$ or R_1 and R_2 together can form a $\text{C}_3\text{-C}_7\text{-cycloalkyl}$ ring, a carbonyl bond $\text{C}=\text{O}$ or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula




R_3 , R_4 , R_5 , R_6 , and R_7 independently are hydrogen, halogen, -CN, nitro, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)R₈-C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R_8 , R_9 , R_{10} each independently is hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently -C(R₃)=, -C(R₃)=C(R₄)-, -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR₈C(=O)-, NR₈S(=O)₂-, -C(=O)NR₈-, -S-, -S(=O)-, -S(=O)₂-, -S(=O)₂NR₈-, -C(=O)-O-, -O-C(=O)-, -C(=NR₈)NR₉-, C(=NOR₈)NR₉-, -NR₈C(=NOR₉)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula



R₃, R₄, R₅ and R₆ independently are as defined above;

D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;


B represents a single bond, -C(=O)-C₂-C₆-alkenyl-, -C(=O)-C₂-C₆-alkynyl-, -C(=O)-C₀-C₂-alkyl-, C(=O)-O-, -C(=O)NR₈-C₀-C₂-alkyl-, -C(=NR₈)NR₉-S(=O)-C₀-C₂-alkyl-, -S(=O)₂C₀-C₂-alkyl-, -S(=O)₂NR₈-C₀-C₂-alkyl-, C(=NR₈)-C₀-C₂-alkyl-, C(=NOR₈)-C₀-C₂-alkyl- or -C(=NOR₈)NR₉-C₀-C₂-alkyl-;

R₈ and R₉, independently are as defined above;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 3. (Currently amended) A compound according to claim 1 or 2 having the formula I-B




Wherein

R₁ and R₂ represent independently hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C₁-C₆-alkoxy

or R₁ and R₂ together can form a C₃-C₇-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H in P & Q represent independently -C(R₃)=, -C(R₃)=C(R₄)-, -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

D, E and G in A independently are as defined for A in claim 1;

B represents a single bond, $-C(=O)-C_0-C_2$ -alkyl-, $-C(=O)-C_2-C_6$ -alkenyl-, $-C(=O)-C_2-C_6$ -alkynyl-, $-C(=O)-O-$, $-C(=O)NR_8-C_0-C_2$ -alkyl-, $-C(=NR_8)NR_9-S(=O)-C_0-C_2$ -alkyl-, $-S(=O)_2-C_0-C_2$ -alkyl-, $-S(=O)_2NR_8-C_0-C_2$ -alkyl-, $C(=NR_8)-C_0-C_2$ -alkyl-, $-C(=NOR_8)-C_0-C_2$ -alkyl- or $-C(=NOR_8)NR_9-C_0-C_2$ -alkyl-;
 R_8 and R_9 , independently are as defined above;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.


Claim 4. (Currently amended) A compound according to claim 1 or 2 having the formula I-C



Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6 -alkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, arylalkyl, heteroarylalkyl, hydroxy, hydroxyalkyl, C_1-C_6 -alkoxy or R_1 and R_2 together can form a carbonyl bond $C=O$ or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3 , R_4 , R_5 , R_6 , and R_7 independently are hydrogen, halogen, $-CN$, nitro, C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_3-C_7 -cycloalkylalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, halo- C_1-C_6 -alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, $-OR_8$, $-NR_8R_9$, $-C(=NR_{10})NR_8R_9$,

$N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, $-C(=O)_2R_8$, $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, $-CN$, C_1-C_6 -alkyl, $-O(C_0-C_6$ -alkyl), $-O(C_3-C_7$ -cycloalkylalkyl), $-O(aryl)$, $-O(heteroaryl)$, $-O(C_1-C_3$ -alkylaryl), $-O(C_1-C_3$ -alkylheteroaryl), $-N(C_0-C_6$ -alkyl)(C_0-C_3 -alkylaryl) or $-N(C_0-C_6$ -alkyl)(C_0-C_3 -alkylheteroaryl) groups;

R_8 , R_9 , R_{10} each independently is hydrogen, C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_3-C_7 -cycloalkylalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, halo- C_1-C_6 -alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, C_1-C_6 -alkyl, $-O(C_0-C_6$ -alkyl), $-O(C_3-C_7$ -cycloalkylalkyl), $-O(aryl)$, $-O(heteroaryl)$, $-N(C_0-C_6$ -alkyl)(C_0-C_6 -alkyl), $-N(C_0-C_6$ -alkyl)(C_3-C_7 -cycloalkyl) or $-N(C_0-C_6$ -alkyl)(aryl) substituents;

D, E, F, G and H represent independently $-C(R_3)=$, $-C(R_3)=C(R_4)-$, $-C(=O)-$, $-C(=S)-$, $-O-$, $-N=$, $-N(R_3)-$ or $-S-$;


B represents a single bond, $-C(=O)-C_0-C_2$ -alkyl-, $-C(=O)-C_2-C_6$ -alkenyl-, $-C(=O)-C_2-C_6$ -alkynyl-, $-C(=O)-O-$, $-C(=O)NR_8-C_0-C_2$ -alkyl-, $-C(=NR_8)NR_9-S(=O)-C_0-C_2$ -alkyl-, $-S(=O)_2-C_0-C_2$ -alkyl-, $-S(=O)_2NR_8-C_0-C_2$ -alkyl-, $C(=NR_8)-C_0-C_2$ -alkyl-, $-C(=NOR_8)-C_0-C_2$ -alkyl- or $-C(=NOR_8)NR_9-C_0-C_2$ -alkyl-;

R_8 and R_9 , independently are as defined above;

Any N may be an N-oxide.






or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 5. (Currently amended) A compound according to claim 1 or 2 having the formula I-D



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;


R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently $-\text{C}(\text{R}_3)=$, $-\text{C}(\text{R}_3)=\text{C}(\text{R}_4)-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{O}-$, $-\text{N}=$, $-\text{N}(\text{R}_3)-$ or $-\text{S}-$;

Any N may be an N-oxide.


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 6. (Currently amended) A compound according to claim 1 or 2 having the formula I-E



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



$\text{R}_3, \text{R}_4, \text{R}_5, \text{R}_6$, and R_7 independently are hydrogen, halogen, $-\text{CN}$, nitro, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, $\text{C}_3\text{-C}_7\text{-cycloalkylalkyl}$, $\text{C}_2\text{-C}_6\text{-alkenyl}$, $\text{C}_2\text{-C}_6\text{-alkynyl}$, halo- $\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{heteroaryl}$, $-\text{heteroarylalkyl}$, $-\text{arylalkyl}$, $-\text{aryl}$, $-\text{OR}_8$, $-\text{NR}_8\text{R}_9$, $-\text{C}(=\text{NR}_{10})\text{NR}_8\text{R}_9$, $\text{N}(=\text{NR}_{10})\text{NR}_8\text{R}_9$, $-\text{NR}_8\text{COR}_9$, $\text{NR}_8\text{CO}_2\text{R}_9$, $\text{NR}_8\text{SO}_2\text{R}_9$, $-\text{NR}_{10}\text{CO}$, NR_8R_9 , $-\text{SR}_8$, $-\text{S}(=\text{O})\text{R}_8$, $-\text{S}(=\text{O})_2\text{R}_8$, $-\text{S}(=\text{O})_2\text{NR}_8\text{R}_9$, $-\text{C}(=\text{O})\text{R}_8$, $-\text{C}(=\text{O})_2\text{R}_8$, $-\text{C}(=\text{O})\text{NR}_8\text{R}_9$, $-\text{C}(=\text{NR}_8)\text{R}_9$, or $\text{C}(=\text{NOR}_8)\text{R}_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{O}(\text{C}_0\text{-C}_6\text{-alkyl})$, $-\text{O}(\text{C}_3\text{-C}_7\text{-cycloalkylalkyl})$,

-O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;


R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently -C(R₃)=, -C(R₃)=C(R₄), -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

Any N may be an N-oxide.


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 7. (Currently amended) A compound according to claim 1 or 2 having the formula I-F



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3 , R_4 , R_5 , R_6 , and R_7 independently are hydrogen, halogen, -CN, nitro, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, - OR_8 , - NR_8R_9 , - $C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, - NR_8COR_9 , $NR_8CO_2R_9$, $NR_8SO_2R_9$, - $NR_{10}CO$ NR_8R_9 , - SR_8 , - $S(=O)R_8$, - $S(=O)_2R_8$, - $S(=O)_2NR_8R_9$, - $C(=O)R_8$, - $C(=O)_2R_8$, - $C(=O)NR_8R_9$, - $C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, - $O(C_0$ - C_6 -alkyl), - $O(C_3$ - C_7 -cycloalkylalkyl), - $O(aryl)$, - $O(heteroaryl)$, - $O(C_1$ - C_3 -alkylaryl), - $O(C_1$ - C_3 -alkylheteroaryl), - $N(C_0$ - C_6 -alkyl)(C_0 - C_3 -alkylaryl) or - $N(C_0$ - C_6 -alkyl)(C_0 - C_3 -alkylheteroaryl) groups;


R_8 , R_9 , R_{10} each independently is hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, - $O(C_0$ - C_6 -alkyl), - $O(C_3$ - C_7 -cycloalkylalkyl), - $O(aryl)$, - $O(heteroaryl)$, - $N(C_0$ - C_6 -alkyl)(C_0 - C_6 -alkyl), - $N(C_0$ - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or - $N(C_0$ - C_6 -alkyl)(aryl) substituents;

D, E, F, G and H represent independently - $C(R_3)=$, - $C(R_3)=C(R_4)-$, - $C(=O)-$, - $C(=S)-$, - $O-$, - $N=$, - $N(R_3)-$ or - $S-$;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.


Claim 8. (Currently amended) A compound according to claim 1 having the formula I-G



Wherein

R₁ and R₂ represent independently hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C₁-C₆-alkoxy or R₁ and R₂ together can form a C₃-C₇-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula




R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₁-C₆-alkenyl, C₁-C₆-alkynyl, halo-C₁-C₆-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently $-\text{C}(\text{R}_3)=$, $-\text{C}(\text{R}_3)=\text{C}(\text{R}_4)-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{O}-$, $-\text{N}=$, $-\text{N}(\text{R}_3)-$ or $-\text{S}-$;

A is azo $-\text{N}=\text{N}-$, ethyl, ethenyl, ethynyl, $-\text{NR}_8\text{C}(=\text{O})-$, $\text{NR}_8\text{S}(=\text{O})_2-$, $-\text{C}(=\text{O})\text{NR}_8-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{S}(=\text{O})_2-$, $-\text{S}(=\text{O})_2\text{NR}_8-$, $-\text{C}(=\text{O})\text{O}-$, $-\text{O}\text{C}(=\text{O})-$, $-\text{C}(=\text{N}\text{R}_8)\text{NR}_9-$, $\text{C}(=\text{N}\text{R}_8)\text{NR}_9-$, $-\text{NR}_8\text{C}(=\text{N}\text{R}_9)-$, $=\text{N}\text{O}-$, $-\text{O}\text{N}=\text{CH}-$ or a group aryl or heteroaryl of formula



R_3 , R_4 , R_5 and R_6 independently are as defined above;

D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;

B represents a single bond, $-\text{C}(=\text{O})\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{C}(=\text{O})\text{C}_2\text{C}_6\text{-alkenyl-}$, $-\text{C}(=\text{O})\text{C}_2\text{C}_6\text{-alkynyl-}$, $-\text{C}(=\text{O})\text{O}-$, $-\text{C}(=\text{O})\text{NR}_8\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{C}(=\text{N}\text{R}_8)\text{NR}_9\text{S}(=\text{O})\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{S}(=\text{O})_2\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{S}(=\text{O})_2\text{NR}_8\text{C}_0\text{C}_2\text{-alkyl-}$, $\text{C}(=\text{N}\text{R}_8)\text{C}_0\text{C}_2\text{-alkyl-}$, $-\text{C}(=\text{N}\text{R}_8)\text{NR}_9\text{C}_0\text{C}_2\text{-alkyl-}$;

R_8 and R_9 , independently are as defined above;


J represents $-\text{C}(\text{R}_{11}, \text{R}_{12})$, $-\text{O}-$, $-\text{N}(\text{R}_{11})-$ or $-\text{S}-$;

R_{11} , R_{12} independently are hydrogen, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, $\text{C}_3\text{-C}_7\text{-cycloalkylalkyl}$, $\text{C}_2\text{-C}_6\text{-alkenyl}$, $\text{C}_2\text{-C}_6\text{-alkynyl}$, halo- $\text{C}_1\text{-C}_6\text{-alkyl}$, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, $-\text{CN}$, $\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{O}(\text{C}_0\text{-C}_6\text{-alkyl})$, $-\text{O}(\text{C}_3\text{-C}_7\text{-cycloalkylalkyl})$, $-\text{O}(\text{aryl})$, $-\text{O}(\text{heteroaryl})$, $-\text{N}(\text{C}_0\text{-C}_6\text{-alkyl})(\text{C}_0\text{-C}_6\text{-alkyl})$, $-\text{N}(\text{C}_0\text{-C}_6\text{-alkyl})(\text{C}_3\text{-C}_7\text{-cycloalkyl})$ or $-\text{N}(\text{C}_0\text{-C}_6\text{-alkyl})(\text{aryl})$ substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.


Claim 9. (Currently amended) A compound according to claim 1 or 8 having the formula I-H



Wherein

R₁ and R₂ represent independently hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C₁-C₆-alkoxy or R₁ and R₂ together can form a C₃-C₇-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₈-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)R₈—C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen,

-CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H in P & Q represent independently -C(R₃)=, -C(R₃)=C(R₄)-, -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

D, E and G in A are independently as defined for A in claim 1;

B represents a single bond, -C(=O)-C₀-C₂-alkyl-, -C(=O)-C₂-C₆-alkenyl-, -C(=O)-C₂-C₆-alkynyl-, -C(=O)-O-, -C(=O)NR₈-C₀-C₂-alkyl-, -C(=NR₈)NR₉-S(=O)-C₀-C₂-alkyl-, -S(=O)₂-C₀-C₂-alkyl-, -S(=O)₂NR₈-C₀-C₂-alkyl-, C(=NR₈)-C₀-C₂-alkyl-, -C(=NOR₈)-C₀-C₂-alkyl- or -C(=NOR₈)NR₉-C₀-C₂-alkyl-;

R₈ and R₉, independently are as defined above;


J represents -C(R₁₁, R₁₂), -O-, -N(R₁₁)- or -S-;

R₁₁, R₁₂ independently are hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.


Claim 10. (Currently amended) A compound according to claim 1 or 8 having the formula I-I



Wherein

R₁ and R₂ represent independently hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, hydroxyalkyl, C₁-C₆-alkoxy or R₁ and R₂ together can form a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R_8 , R_9 , R_{10} each independently is hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C_0 - C_6 -alkyl), -O(C_3 - C_7 -cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0 - C_6 -alkyl)(C_0 - C_6 -alkyl), -N(C_0 - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or -N(C_0 - C_6 -alkyl)(aryl) substituents;

D, E, F, G and H represent independently -C(R_3)=, -C(R_3)=C(R_4), -C(=O)-, -C(=S)-, -O-, -N=, -N(R_3)- or -S-;


B represents a single bond, -C(=O)- C_0 - C_2 -alkyl-, -C(=O)- C_2 - C_6 -alkenyl-, -C(=O)- C_2 - C_6 -alkynyl-, -C(=O)-O-, -C(=O)NR₈- C_0 - C_2 -alkyl-, -C(=NR₈)NR₉-S(=O)- C_0 - C_2 -alkyl-, -S(=O)₂- C_0 - C_2 -alkyl-, -S(=O)₂NR₈- C_0 - C_2 -alkyl-, C(=NR₈)- C_0 - C_2 -alkyl-, C(=NOR₈)- C_0 - C_2 -alkyl- or -C(=NOR₈)NR₉- C_0 - C_2 -alkyl-;
 R_8 and R_9 , independently are as defined above;

J represents -C(R_{11} , R_{12}), -O-, -N(R_{11})- or -S-;
 R_{11} , R_{12} independently are hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C_0 - C_6 -alkyl), -O(C_3 - C_7 -cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0 - C_6 -alkyl)(C_0 - C_6 -alkyl), -N(C_0 - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or -N(C_0 - C_6 -alkyl)(aryl) substituents;

Any N may be an N-oxide;


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 11. (Currently amended) A compound according to claim 1 or 8 having the formula I-J



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6 , and R_7 independently are hydrogen, halogen, -CN, nitro, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C_0 - C_6 -alkyl), -O(C_3 - C_7 -cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C_1 - C_3 -alkylaryl), -O(C_1 - C_3 -alkylheteroaryl), -N(C_0 - C_6 -alkyl)(C_0 - C_3 -alkylaryl) or -N(C_0 - C_6 -alkyl)(C_0 - C_3 -alkylheteroaryl) groups;

R_8 , R_9 , R_{10} each independently is hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, -O(C_0 - C_6 -alkyl), -O(C_3 - C_7 -cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0 - C_6 -alkyl)(C_0 - C_6 -alkyl), -N(C_0 - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or -N(C_0 - C_6 -alkyl)(aryl) substituents;


D, E, F, G and H represent independently $-C(R_3)=$, $-C(R_3)=C(R_4)-$, $-C(=O)-$, $-C(=S)-$, $-O-$, $-N=$, $-N(R_3)-$ or $-S-$;

J represents $-C(R_{11}, R_{12})$, $-O-$, $-N(R_{11})-$ or $-S-$;
 R_{11}, R_{12} independently are hydrogen, C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_3-C_7 -cycloalkylalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, halo- C_1-C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, C_1-C_6 -alkyl, $-O(C_0-C_6$ -alkyl), $-O(C_3-C_7$ -cycloalkylalkyl), $-O(aryl)$, $-O(heteroaryl)$, $-N(C_0-C_6$ -alkyl)(C_0-C_6 -alkyl), $-N(C_0-C_6$ -alkyl)(C_3-C_7 -cycloalkyl) or $-N(C_0-C_6$ -alkyl)(aryl) substituents;

Any N may be an N-oxide;


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 12. (Currently amended) A compound according to claim 1 or 8 having the formula I-K



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6 , and R_7 independently are hydrogen, halogen, $-CN$, nitro, C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_3-C_7 -cycloalkylalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, halo- C_1-C_6 -

alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, ~~-C(=O)R₈~~, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;


D, E, F, G and H represent independently -C(R₃)=, -C(R₃)=C(R₄), -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

J represents -C(R₁₁, R₁₂), -O-, -N(R₁₁)- or -S-;
R₁₁, R₁₂ independently are hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

Any N may be an N-oxide;


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 13. (Currently amended) A compound according to claim 1 or 8 having the formula I-L



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -S(=O)₂NR₈R₉, -C(=O)R₈, -C(=O)R₈-C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;


D, E, F, G and H represent independently $-C(R_3)=$, $-C(R_3)=C(R_4)-$, $-C(=O)-$, $-C(=S)-$, $-O-$, $-N=$, $-N(R_3)-$ or $-S-$;

J represents $-C(R_{11}, R_{12})$, $-O-$, $-N(R_{11})-$ or $-S-$;
 R_{11}, R_{12} independently are hydrogen, C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_3-C_7 -cycloalkylalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkynyl, halo- C_1-C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, C_1-C_6 -alkyl, $-O(C_0-C_6$ -alkyl), $-O(C_3-C_7$ -cycloalkylalkyl), $-O(aryl)$, $-O(heteroaryl)$, $-N(C_0-C_6$ -alkyl)(C_0-C_6 -alkyl), $-N(C_0-C_6$ -alkyl)(C_3-C_7 -cycloalkyl) or $-N(C_0-C_6$ -alkyl)(aryl) substituents;

Any N may be an N-oxide;


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 14. (Currently amended) A compound according to claim 1 or 8 having the formula I-M



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3 , R_4 , R_5 , R_6 , and R_7 independently are hydrogen, halogen, -CN, nitro, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, - OR_8 , - NR_8R_9 , - $C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, - NR_8COR_9 , $NR_8CO_2R_9$, $NR_8SO_2R_9$, - $NR_{10}CO$ NR_8R_9 , - SR_8 , - $S(=O)R_8$, - $S(=O)_2R_8$, - $S(=O)_2NR_8R_9$, - $C(=O)R_8$, - $C(=O)_2R_8$, - $C(=O)NR_8R_9$, - $C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, - $O(C_0$ - C_6 -alkyl), - $O(C_3$ - C_7 -cycloalkylalkyl), - $O(aryl)$, - $O(heteroaryl)$, - $O(C_1$ - C_3 -alkylaryl), - $O(C_1$ - C_3 -alkylheteroaryl), - $N(C_0$ - C_6 -alkyl)(C_0 - C_3 -alkylaryl) or - $N(C_0$ - C_6 -alkyl)(C_0 - C_3 -alkylheteroaryl) groups;

R_8 , R_9 , R_{10} each independently is hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, - $O(C_0$ - C_6 -alkyl), - $O(C_3$ - C_7 -cycloalkylalkyl), - $O(aryl)$, - $O(heteroaryl)$, - $N(C_0$ - C_6 -alkyl)(C_0 - C_6 -alkyl), - $N(C_0$ - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or - $N(C_0$ - C_6 -alkyl)(aryl) substituents;


D, E, F, G and H represent independently - $C(R_3)=$, - $C(R_3)=C(R_4)-$, - $C(=O)-$, - $C(=S)-$, - $O-$, - $N=$, - $N(R_3)-$ or - $S-$;

J represents - $C(R_{11}, R_{12})$, - $O-$, - $N(R_{11})-$ or - $S-$;
 R_{11} , R_{12} independently are hydrogen, C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_7 -cycloalkylalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, halo- C_1 - C_6 -alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1 - C_6 -alkyl, - $O(C_0$ - C_6 -alkyl), - $O(C_3$ - C_7 -cycloalkylalkyl), - $O(aryl)$, - $O(heteroaryl)$, - $N(C_0$ - C_6 -alkyl)(C_0 - C_6 -alkyl), - $N(C_0$ - C_6 -alkyl)(C_3 - C_7 -cycloalkyl) or - $N(C_0$ - C_6 -alkyl)(aryl) substituents;

Any N may be an N-oxide;


or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 15. (Currently amended) A compound according to claim 1 or 8 having the formula I-N



Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R₃, R₄, R₅, R₆, and R₇ independently are hydrogen, halogen, -CN, nitro, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR₈, -NR₈R₉, -C(=NR₁₀)NR₈R₉, N(=NR₁₀)NR₈R₉, -NR₈COR₉, NR₈CO₂R₉, NR₈SO₂R₉, -NR₁₀CO NR₈R₉, -SR₈, -S(=O)R₈, -S(=O)₂R₈, -NR₈R₉, -C(=O)R₈, -C(=O)₂R₈, -C(=O)NR₈R₉, -C(=NR₈)R₉, or C(=NOR₈)R₉ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C₁-C₃-alkylaryl), -O(C₁-C₃-alkylheteroaryl), -N(C₀-C₆-alkyl)(C₀-C₃-alkylaryl) or -N(C₀-C₆-alkyl)(C₀-C₃-alkylheteroaryl) groups;

R₈, R₉, R₁₀ each independently is hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl),

-O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

D, E, F, G and H represent independently -C(R₃)=, -C(R₃)=C(R₄), -C(=O)-, -C(=S)-, -O-, -N=, -N(R₃)- or -S-;

J represents -C(R₁₁, R₁₂), -O-, -N(R₁₁)- or -S-;
R₁₁, R₁₂ independently are hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₇-cycloalkylalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, halo-C₁-C₆-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C₁-C₆-alkyl, -O(C₀-C₆-alkyl), -O(C₃-C₇-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C₀-C₆-alkyl)(C₀-C₆-alkyl), -N(C₀-C₆-alkyl)(C₃-C₇-cycloalkyl) or -N(C₀-C₆-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 16. (Currently amended) A compound according to claim 1-claims 1 to 15, which can exist as optical isomers, wherein said compound is either the racemic mixture or the individual optical isomers.

Claim 17. (Currently amended) A compound according to claim 1-claims 1 to 16, wherein said compounds are selected from:

(4-Fluoro-phenyl)-[3-(4-fluoro-phenylethynyl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-methanone
(S)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(S)-(thiophen-2-yl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-2-pyrazin-2-yl-thiazol-5-yl)-methanone
(2,4-Difluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(3,4,5-trifluoro-phenyl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(5-pyridin-2-yl-thiophen-2-yl)-methanone

Cyclopentyl-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3,4-Difluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

Benzothiazol-6-yl-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3,5-Dimethyl-isoxazol-4-yl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(2,4,6-trifluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

{(S)-3-[3-(2,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-p-tolyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{(S)-3-[2-(3,4-difluoro-phenyl)-1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-thiophen-3-yl-methanone

(4-Fluoro-phenyl)-[3-(5-phenyl-tetrazol-2-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(3,4-Difluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone.

Claim 18. (Currently amended) A compound according to claim 1—claims 1 to 16, wherein said compounds are selected from:

{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone

{3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone

(4-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(3-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(3-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(3-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(*R*)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-
methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-phenyl-thiazol-4-yl)-
methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-methyl-6-trifluoromethyl-
pyridin-3-yl)-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-[1,2,3]thiadiazol-4-yl-
methanone
Benzothiazol-2-yl-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-isoxazol-3-yl)-
methanone
(1,5-Dimethyl-1H-pyrazol-3-yl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-
yl}-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-
methanone
4-{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carbonyl}-benzonitrile
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-isoxazol-5-yl-methanone
(3-Chloro-4-fluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-phenyl-2H-pyrazol-3-yl)-
methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-2-phenyl-2H-
[1,2,3]triazol-4-yl)-methanone
(4-Fluoro-3-methyl-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-
methanone
{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(3-methyl-thiophen-2-yl)-
methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1-methyl-1H-pyrrol-2-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-thiazol-2-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-thiazol-5-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1H-indol-5-yl)-methanone

2-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-ethanone

3-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-propan-1-one

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-isoquinolin-3-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-quinoxalin-6-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-benzoimidazol-6-yl-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-naphthalen-1-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

{(S)-3-[3-(2,6-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(2-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-naphthalen-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-methanone

(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-amide

(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-methyl-amide.

(E)-3-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-propanone

1-(4-{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-carbonyl)-piperidin-1-yl)-ethanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3,4-Difluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone.

Claim 19. (Currently amended) A compound according to claim 1—claims 1 to 16, wherein said compounds are selected from:

(4-fluorophenyl)-{(S)-3-[5-(4-fluorophenyl)isoxazol-3-yl]piperidin-1-yl}methanone
(4-fluorophenyl)-{(S)- 3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]piperidin-1-yl}methanone
(4-fluorophenyl)-{(S)- 3-[4-(4-fluorophenyl)-1H-imidazol-1-yl]piperidin-1-yl}methanone
(4-fluorophenyl)-{(S)- 3-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]piperidin-1-yl }methanone
N-(1-(4-fluorobenzoyl)piperidin-3-yl)-4-fluorobenzamid
(2-Fluoro-phenyl)-{3-[2-(4-fluoro-phenyl)-oxazol-5-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-oxazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-thiazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[2-(4-fluoro-phenyl)-thiazol-5-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone
(2-fluorophenyl)(3-(5-(4-fluorophenyl)isoxazol-3-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(4-(4-fluorophenyl)-1H-imidazol-1-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(4-(4-fluorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl)methanone
N-(1-(4-fluorobenzoyl)piperidin-3-yl)-2-fluorobenzamid
(2-Fluoro-phenyl)-{3-[2-(3,4-fluoro-phenyl)-oxazol-5-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-oxazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-thiazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[2-(3,4-fluoro-phenyl)-thiazol-5-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone
(2-fluorophenyl)(3-(5-(3,4-fluorophenyl)isoxazol-3-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(5-(3,4-fluorophenyl)-1H-imidazol-2-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(4-(3,4-fluorophenyl)-1H-imidazol-1-yl)piperidin-1-yl)methanone
(2-fluorophenyl)(3-(4-(3,4-fluorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl)methanone
N-(1-(3,4-fluorobenzoyl)piperidin-3-yl)-2-fluorobenzamid.

Claim 20. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1–claims 1 to 19 and pharmaceutically acceptable carriers and/or excipients.

Claim 21. (Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claim 1–claims 1 to 20.

Claim 22. (Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 positive allosteric modulators (enhancer), comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound according to claim 1–claims 1 to 20.

Claim 23. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of anxiety disorders: Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, comprising administering an effective amount of a compound according to claim 1–claims 1 to 20.

Claim 24. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of childhood disorders: Attention-Deficit/Hyperactivity Disorder), comprising administering an effective amount of a compound according to claim 1–claims 1 to 20.

Claim 25. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of eating Disorders (Anorexia Nervosa, Bulimia Nervosa), comprising administering an effective amount of a compound according to claim 1–claims 1 to 20.

Claim 26. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of mood disorders: Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, Substance-Induced Mood Disorder, comprising administering an effective amount of a compound according to claim 1-claims 1 to 20.

Claim 27. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of psychotic disorders: Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, Substance-Induced Psychotic Disorder, comprising administering an effective amount of a compound according to claim 1-claims 1 to 20.

Claim 28. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of cognitive disorders: Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, Mild Cognitive Impairment, comprising administering an effective amount of a compound according to claim 1-claims 1 to 20.

Claim 29. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of personality disorders: Obsessive-Compulsive Personality Disorder, Schizoid, Schizotypal disorder, comprising administering an effective amount of a compound according to claim 1-claims 1 to 20.

Claim 30. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of substance-related disorders: Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder, Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, Opioid withdrawal, comprising administering an effective amount of a compound according to claim 1-claims 1 to 20.

Claims 31-32. (Cancelled)

Claim 33. (new) A method for treating a mammal suffering from or susceptible to Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 34. (new) A method for treating a mammal suffering from or susceptible to Attention-Deficit/Hyperactivity Disorder, or an Eating disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 35. (new) A method for treating a mammal suffering from or susceptible to an Eating disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 36. (new) A method for treating a mammal suffering from or susceptible to Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, or Substance-Induced Mood Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 37. (new) A method for treating a mammal suffering from or susceptible to Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, or Substance-Induced Psychotic Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 38. (new) A method for treating a mammal suffering from or susceptible to Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, or Mild Cognitive Impairment, the method comprising administering a compound of claim 1 to the mammal.

Claim 39. (new) A method for treating a mammal suffering from or susceptible to Obsessive-Compulsive Personality Disorder, Schizoid, or Schizotypal disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 40. (new) A method for treating a mammal suffering from or susceptible to Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder, Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, or Opioid withdrawal, the method comprising administering a compound of claim 1 to the mammal.

Claim 41. (new) A pharmaceutical composition comprising a compound of claim 1.

Claim 42. (new) A pharmaceutical composition of claim 41 further comprising a pharmaceutically acceptable carrier.

Claim 43. (new) A method to prepare a tracer to for imaging metabotropic glutamate receptors, comprising using a compound of claim 1.